Snapshot
Key Ratio
Peers
Financials
Ownership
News
Events

RATING

RECOMMENDATION

Strong Sell

  • ROFR Required

  • Available in Depository:

  • NSDL

  • CDSL

  • Available for Investment:

  • Primary

  • Secondary

RATING

RECOMMENDATION

Strong Sell

Business Type

Traditional Business

  • Investment Checklist

Management

Accounting Practice

Profitability

Solvency

Growth

Valuation

Snapshot
Key Ratio
Peers
Financials
Ownership
News
Events

RATING

RECOMMENDATION

Strong Sell

Business Type

Traditional Business

  • Arch Pharmalabs Growth

Get detailed information about the Arch Pharmalabs Share Price. In this research report, you will get to know about Arch Pharmalabs Peers data. In addition, get the complete details about the Net Profit Growth, Revenue Growth and Book Value Growth.

Arch Pharmalabs Revenue Growth

Growth in %

  • 26.56%

    1 Year

  • 62.27%

    2 Year

There is a significant increase in total income primarily on account of higher revenue from operations in 2020 in comparison to 2019. Company has increased its sale of API/Intermediate from INR 47,323 lakhs in 2019 to INR 62,987 lakhs in 2020. 

Arch Pharmalabs Net Profit Growth(PAT)

Growth in %

  • NA

    1 Year

  • NA

    2 Year

Profit after tax showed a gradual decline due to higher cost of materials consumed. Chemical consumption cost has been increased from INR 39,935.94 lakhs in 2019 to INR 53,764 lakhs in 2020.

Arch Pharmalabs EPS Growth

Growth in %

  • NA

    1 Year

  • NA

    2 Year

EPS showed a significant decline primarily because of higher loss in 2020 as compared to 2019.

  • Arch Pharmalabs Book Value Growth

Growth in %

  • 14.62%

    1 Year

Arch Pharmalabs EBITDA Growth

Growth in %

  • 10.31%

    1 Year

  • NA

    2 Year

Arch Pharmalabs Operating Profit Growth

Growth in %

  • 38.67%

    1 Year

  • NA

    2 Year

Arch Pharmalabs Asset Growth

Growth in %

  • -3.76%

    1 Year

  • 3.07%

    2 Year

There is a gradual decline in total assets primarily on account of lower trade receivables in 2020 as against 2019. Trade receivables under 6 months have been decreased from INR 30,096 lakhs in 2019 to INR 15,324 lakhs in 2020.

Arch Pharmalabs Cash Flow from Operations

Growth in %

  • 1087.60%

    1 Year

  • NA

    2 Year

There is significant increase in cash from operations primarily on account of higher change in trade receivables in 2020 against 2019.

  • Arch Pharmalabs Solvency Ratios

Arch Pharmalabs D/E Ratio

There is a significant decrease in debt primarily on account of lower long term borrowings. Other term loans have been decreased from INR 3,32746 lakhs in 2019 to INR 2,97,201.18 lakhs in 2020.

Arch Pharmalabs Current Ratio

There is a marginal decrease in current and quick ratio primarily due to increased other current liabilities resulted majorly from higher current maturities of debt. 

Arch Pharmalabs Quick Ratio

Arch Pharmalabs Interest Coverage Ratio

  • Arch Pharmalabs Operating Efficiency

Arch Pharmalabs Operating Profit EBIT Margin(OPM)

There is a marginal increase in EBIT, EBITDA, PBT, PAT margin% primarily on account of higher revenue from operations in 2020 in comparison to 2019. Company has increased its sale of API/Intermediate from INR 47,323 lakhs in 2019 to INR 62,987 lakhs in 2020. 

Arch Pharmalabs Profit Before Tax Margin (PBT Margin)

Arch Pharmalabs Profit After Tax Margin (PAT Margin)

  • Arch Pharmalabs Profitablity Ratio

Arch Pharmalabs Return on Equity(RoE)

There is a marginal increase in ROE primarily on account of lower surplus during the year 2020 as compared to 2019. Surplus was INR -2,77,434 lakhs in 2019 and INR -2,93,385 lakhs in 2020.

Arch Pharmalabs Return on Capital Employed(RoCE)

There is a marginal increase in ROCE primarily on account of lower capital employed resulted from higher total other current liabilities. Current maturities of debt have been increased from INR 12,258 lakhs in 2019 to INR 53,251 lakhs in 2020.

Arch Pharmalabs Return to Assets (RoA)

There is a marginal decrease in ROA and it is negative as company has incurred loss during the year 2019 and 2020. Company has earned loss majorly on account of higher cost of materials consumed of Chemicals from INR 39,936 lakhs in 2019 to INR INR 53,764 lakhs in 2020.

  • Arch Pharmalabs Valuation Ratios

Arch Pharmalabs Earning Yield

  • ROFR Required

Available in Depository

  • NSDL

  • CDSL

Available for Investment

  • Primary

  • Secondary

  • Investment Checklist

Management

Accounting Practice

Profitability

Solvency

Growth

Valuation